UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The Lancet (British edition), ISSN 0140-6736, 2008, Volume 372, Issue 9632, pp. 31 - 39
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Thiophenes - therapeutic use | Double-Blind Method | Drug Administration Schedule | Thiophenes - adverse effects | Humans | Middle Aged | Morpholines - administration & dosage | Arthroplasty, Replacement, Hip | Male | Thiophenes - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Fibrinolytic Agents - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage | Morpholines - adverse effects | Morpholines - therapeutic use | Health care | Medical imaging | Hospitals | Protease inhibitors | Surgery | Tomography | Joint surgery | Drug therapy | Patients | Veins & arteries | Index Medicus | Abridged Index Medicus | Thiophenes/administration & dosage/adverse effects/therapeutic use | use | Arthroplasty | Replacement | Venous Thromboembolism/prevention & control | Morpholines/administration & dosage/adverse effects/therapeutic use | Kirurgi | Hip | 80 and over | Enoxaparin/administration & dosage/adverse effects/therapeutic use | Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic
Journal Article
Thrombosis and haemostasis, ISSN 0340-6245, 01/2009, Volume 101, Issue 1, pp. 77 - 85
anticoagulants | thrombosis | prophylaxis | Embolism | Meta-analysis | Anticoagulants | Thrombosis | Prophylaxis | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Hematologic and hematopoietic diseases | Biological and medical sciences | Blood coagulation. Blood cells | Molecular and cellular biology | Medical sciences | Platelet diseases and coagulopathies | Venous Thromboembolism - mortality | Anticoagulants - administration & dosage | Arthroplasty, Replacement, Knee - adverse effects | Humans | Dabigatran | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Clinical Trials, Phase III as Topic | Enoxaparin - administration & dosage | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Drug Administration Schedule | Risk Assessment | Administration, Oral | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Arthroplasty, Replacement, Hip - adverse effects | Venous Thromboembolism - etiology | Hemorrhage - chemically induced | Index Medicus | Administration | Phase III as Topic | Benzimidazoles/administration & dosage/adverse effects/therapeutic use | Pyridines/administration & dosage/adverse effects/therapeutic use | Arthroplasty | Replacement | Oral | Clinical Trials | Kirurgi | Knee/adverse effects | Hemorrhage/chemically induced | Venous Thromboembolism/etiology/mortality/prevention & control | Hip/adverse effects | Anticoagulants/administration & dosage/adverse effects/therapeutic use | Surgery | Enoxaparin/administration & dosage/adverse effects/therapeutic use
Journal Article
Thrombosis and haemostasis, ISSN 0340-6245, 04/2011, Volume 105, Issue 4, pp. 721 - 729
Dabigatran etexilate | Oral anticoagulant | Total hip arthroplasty | Venous thromboembolism | Prophylaxis | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Fundamental and applied biological sciences. Psychology | Cardiology. Vascular system | Hematologic and hematopoietic diseases | Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous | Biological and medical sciences | Blood coagulation. Blood cells | Molecular and cellular biology | Medical sciences | Blood and lymphatic vessels | Platelet diseases and coagulopathies | Venous Thromboembolism - mortality | Anticoagulants - administration & dosage | Humans | Middle Aged | Male | Antithrombins - administration & dosage | Dabigatran | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Benzimidazoles - administration & dosage | Hemorrhage - etiology | Injections, Subcutaneous | Female | Venous Thrombosis - prevention & control | Benzimidazoles - adverse effects | beta-Alanine - analogs & derivatives | Postoperative Complications | beta-Alanine - adverse effects | Double-Blind Method | Administration, Oral | Venous Thrombosis - mortality | beta-Alanine - administration & dosage | Anticoagulants - adverse effects | Venous Thrombosis - etiology | Venous Thromboembolism - etiology | Antithrombins - adverse effects | Survival Analysis | Arthroplasty, Replacement, Hip - mortality | Aged | Benzimidazoles | Venous Thrombosis | Oral | Hemorrhage | Antithrombins | Venous Thromboembolism | administration & dosage | Surgery | beta-Alanine | Administration | Anticoagulants | Subcutaneous | Enoxaparin | Arthroplasty | Replacement | prevention & control | Kirurgi | Hip | etiology | Injections | analogs & derivatives | adverse effects | mortality
Journal Article
The New England journal of medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 9, pp. 799 - 808
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Follow-Up Studies | Humans | Middle Aged | Hemorrhage - mortality | Warfarin - adverse effects | Male | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - drug therapy | Warfarin - therapeutic use | Pyridones - administration & dosage | Adult | Female | Pyrazoles - adverse effects | Acute Disease | Double-Blind Method | Administration, Oral | Kaplan-Meier Estimate | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Pyrazoles - administration & dosage | Aged | Hemorrhage - chemically induced | Pyridones - adverse effects | Dosage and administration | Research | Thromboembolism | Drug therapy | Apixaban | Anticoagulants | Warfarin | Heart attacks | Embolisms | Thrombosis | Patients | Bleeding | Veins & arteries | Index Medicus | Abridged Index Medicus | Pyrazoles | Pyridones | Enoxaparin | Factor Xa | Hemorrhage | Life Sciences | Venous Thromboembolism
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 01/2020, Volume 323, Issue 2, pp. 130 - 139
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Single-Blind Method | Pulmonary Embolism - prevention & control | Anticoagulants - administration & dosage | Humans | Middle Aged | Postoperative Complications - prevention & control | Male | Enoxaparin - adverse effects | Factor Xa Inhibitors - administration & dosage | Dose-Response Relationship, Drug | Pyridones - administration & dosage | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Arthroplasty, Replacement, Knee | Female | Venous Thrombosis - prevention & control | Pyrazoles - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Anticoagulants - adverse effects | Preoperative Care | Pyrazoles - administration & dosage | Factor Xa Inhibitors - adverse effects | Aged | Hemorrhage - chemically induced | Pyridones - adverse effects | Knee | Surgical implants | Intravenous administration | Arthroplasty (knee) | Clinical trials | Risk | Criteria | Joint surgery | Joint replacement surgery | Thrombosis | Patients | Bleeding | Embolism | Body mass index | Biomedical materials | Body mass | Body size | Surgery | Monoclonal antibodies | Safety | Thromboembolism | Health risk assessment
Journal Article
European journal of pharmaceutics and biopharmaceutics, ISSN 0939-6411, 12/2016, Volume 109, pp. 113 - 121
Oral LMWH delivery | Hydrophobic ion pairing | Self-emulsifying drug delivery systems (SEDDS) | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Amines - chemistry | Caco-2 Cells | Chemistry, Pharmaceutical - methods | Administration, Oral | Cell Survival | Emulsions - chemistry | Xanthenes - chemistry | Humans | Solubility | Biological Availability | Chromatography, High Pressure Liquid | Drug Carriers - chemistry | Heparin, Low-Molecular-Weight | Drug Delivery Systems | Particle Size | Enoxaparin - administration & dosage | Lipids - chemistry | Emulsifying Agents - chemistry | Enoxaparin - chemistry | Drug Liberation | Oxazines - chemistry | Diffusion | Drugs | Drug delivery systems | Analysis | Vehicles | Index Medicus
Journal Article
Journal of thrombosis and haemostasis, ISSN 1538-7933, 2015, Volume 13, Issue 12, pp. 2187 - 2191
anticoagulants | cancer | enoxaparin | apixaban | venous thromboembolism | Enoxaparin | Anticoagulants | Venous thromboembolism | Apixaban | Cancer | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Recurrence | Anticoagulants - administration & dosage | Humans | Middle Aged | Warfarin - adverse effects | Male | Warfarin - administration & dosage | Enoxaparin - adverse effects | Venous Thromboembolism - drug therapy | Factor Xa Inhibitors - administration & dosage | Venous Thromboembolism - blood | Neoplasms - complications | Pyridones - administration & dosage | Enoxaparin - administration & dosage | Neoplasms - blood | Time Factors | Female | Odds Ratio | Pyrazoles - adverse effects | Venous Thromboembolism - diagnosis | Double-Blind Method | Risk Factors | Logistic Models | Treatment Outcome | Anticoagulants - adverse effects | Chi-Square Distribution | Venous Thromboembolism - etiology | Pyrazoles - administration & dosage | Factor Xa Inhibitors - adverse effects | Aged | Hemorrhage - chemically induced | Pyridones - adverse effects | Clinical trials | Warfarin | Glycosaminoglycans | Thromboembolism | Drug therapy | Analysis | Confidence intervals | Molecular weight | Index Medicus
Journal Article
Critical care clinics, ISSN 0749-0704, 2010, Volume 26, Issue 4, pp. 679 - 688
Pharmacotherapy | Dosing | Obese | Body weight | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Body Mass Index | Vancomycin - administration & dosage | Obesity - drug therapy | Carbapenems - administration & dosage | Humans | Hypnotics and Sedatives - administration & dosage | Heparin - administration & dosage | Antithrombins - administration & dosage | Cephalosporins - administration & dosage | Oxazolidinones - administration & dosage | Penicillins - administration & dosage | Recombinant Proteins - administration & dosage | Obesity - metabolism | Drug Dosage Calculations | Enoxaparin - administration & dosage | Pipecolic Acids - administration & dosage | Quinolones - administration & dosage | Aminoglycosides - administration & dosage | Protein C - administration & dosage | Fibrinolytic Agents - administration & dosage | Lipopeptides - administration & dosage | Safety
Journal Article
Journal of thrombosis and haemostasis, ISSN 1538-7933, 12/2007, Volume 5, Issue 12, pp. 2368 - 2375
Prevention | Oral anticoagulant | Total knee replacement | Surgery | Antithrombotic | Apixaban | Factor Xa inhibitor | Venous thromboembolism | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Pyrazoles - therapeutic use | Venous Thromboembolism - mortality | Arthroplasty, Replacement, Knee - adverse effects | Factor Xa Inhibitors | Humans | Middle Aged | Warfarin - adverse effects | Male | Enoxaparin - therapeutic use | North America | Warfarin - administration & dosage | Enoxaparin - adverse effects | South Australia | Venous Thromboembolism - blood | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Pyridones - administration & dosage | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Pyrazoles - adverse effects | Argentina | Drug Administration Schedule | Risk Assessment | Administration, Oral | Europe | Treatment Outcome | Factor Xa - metabolism | Venous Thromboembolism - etiology | Pyrazoles - administration & dosage | Aged | Fibrinolytic Agents - administration & dosage | Pyridones - therapeutic use | Hemorrhage - chemically induced | Israel | Pyridones - adverse effects | Anticoagulants (Medicine) | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 02/2013, Volume 368, Issue 6, pp. 513 - 523
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Public health. Hygiene-occupational medicine | Public health. Hygiene | Biological and medical sciences | General aspects | Medical sciences | Prevention and actions | Thiophenes - therapeutic use | Acute Disease | Double-Blind Method | Drug Administration Schedule | Factor Xa Inhibitors | Thiophenes - adverse effects | Administration, Oral | Humans | Middle Aged | Anticoagulants - therapeutic use | Male | Enoxaparin - therapeutic use | Anticoagulants - adverse effects | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Injections, Subcutaneous | Adult | Female | Aged | Hemorrhage - chemically induced | Venous Thromboembolism - epidemiology | Morpholines - adverse effects | Morpholines - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Dosage and administration | Product/Service Evaluations | Drug therapy | Thrombosis | Chronically ill | Blood clot | Index Medicus | Abridged Index Medicus | Anticoagulants | Enoxaparin | Factor Xa | Morpholines | Hemorrhage | Life Sciences | Venous Thromboembolism | Thiophenes | Medicin och hälsovetenskap
Journal Article